Onychopathy Following Durvalumab Treatment for Extensive-Stage Small-Cell Lung Cancer: A Case Report

Cuifen Zhang; Ke Wang; Hong Zhang; Jingjing Liu; Chuangjie Zheng; Jiahao Tao; Lizhu Lin; Linzhu Zhai

doi:10.2147/CCID.S415119

Onychopathy Following Durvalumab Treatment for Extensive-Stage Small-Cell Lung Cancer: A Case Report

Clin Cosmet Investig Dermatol. 2023 Sep 5:16:2429-2432. doi: 10.2147/CCID.S415119. eCollection 2023.

Authors

Cuifen Zhang^#¹, Ke Wang^#¹, Hong Zhang¹, Jingjing Liu¹, Chuangjie Zheng¹, Jiahao Tao¹, Lizhu Lin², Linzhu Zhai³

Affiliations

¹ the First Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou, People's Republic of China.
² Cancer Center, the First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, People's Republic of China.
³ Cancer Center, Departments of Radiation Oncology, the First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, People's Republic of China.

^# Contributed equally.

Abstract

Patients treated with immune checkpoint inhibitors (ICIS) are prone to immune related adverse events (irAEs), making it important to pay attention to these adverse events. Herein, we report a case of onychopathy after treatment of extensive small cell lung cancer (ES-SCLC) with durvalumab; this is the first report of onychopathy caused by durvalumab in a patient with lung cancer. The change in the patient's nails mainly manifested in the form of pigmentation and the thickening of the nails. Antifungal ointment was ineffective, and these changes were unrelated to malnutrition or any other factors. In addition, this case shows that onychopathy may occur within 2 years after treatment, indicating that these patients need long-term follow-up.

Keywords: ES-SCLC; durvalumab; immune checkpoint inhibitors; immune-related adverse events; onychopathy.

Publication types

Case Reports

Grants and funding

This work was supported by grants from the Beijing Xisike Clinical Oncology Research Foundation (grant no. Y-2020Sciclone/zb/qn-0005), the National Natural Science Foundation of China (grant nos. 81873147 and 82274604), and the “Double first-class” and high-level university construction discipline (Integrated Traditional Chinese and Western Medicine) reserve talent cultivation project of Guangzhou University of Chinese Medicine (grant no. A1-2601-22-415-014).